Tumor necrosis factor α Inhibition for Alzheimer’s Disease
Open accessAbstract
Tumor necrosis factor α (TNF-α) plays a central role in the pathophysiology of Alzheimer’s disease (AD). Food and Drug Administration–approved biologic TNF-α inhibitors are thus a potential treatment for AD, but they do not cross the blood-brain barrier. In this short review, we discuss the involvement of TNF-α in AD, challenges associated with the development of existing biologic TNF-α inhibitors for AD, and potential therapeutic strategies for targeting TNF-α for AD therapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Given recent experience of high proportion of lack of success in AD clinical trials, more recent trials appear robustly empowered by integration of developments in biomarkers, targeting single primary outcome, enrollment of earlier populations, and innovative trial designs.
“Given the recent experience of a high proportion of lack of success in AD clinical trials on therapeutic agents, more recent trials appear robustly empowered by the integration of developments in biomarkers of AD, of the targeting of a single primary outcome, especially in prodromal AD studies, of the enrollment of earlier populations and the innovative trial designs.91-93”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Glutamate neurotoxicity and diseases of the nervous system
Choi, D. W. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 8,152 · see citing works
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069 · see citing works
An endotoxin-induced serum factor that causes necrosis of tumors
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532 · see citing works
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514 · see citing works
The TNF and TNF Receptor Superfamilies
Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00237-9 · Cited by 3,650 · see citing works
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160 · see citing works
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · see citing works
Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329 · see citing works
Billings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., & LaFerla, F. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.040 · Cited by 1,294 · see citing works
Alzheimer's disease: strategies for disease modification
Citron, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2896 · Cited by 1,060 · see citing works
Tau positron emission tomographic imaging in aging and early <scp>A</scp> lzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986 · see citing works
Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain
Dovey, H. F., John, V., Anderson, J. P., Chen, L. Z., Andrieu, P. D. S. I., Fang, L. Y., Freedman, S. B., Folmer, B., Goldbach, E. G., Holsztynska, E. J., et al. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00012.x · Cited by 870 · see citing works
McCoy, M. K., & Tansey, M. G. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-45 · Cited by 843 · see citing works
Lieberman, A. P., Pitha, P. M., Shin, H. S., & Shin, M. L. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.16.6348 · Cited by 783 · see citing works
Sedger, L. M., & McDermott, M. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.016 · Cited by 774 · see citing works
The Pathogenesis of Senile Plaques
DICKSON, D. W. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199704000-00001 · Cited by 753 · see citing works
Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists
Scallon, B., Cai, A., Solowski, N. L., Rosenberg, A. S., Song, X., Shealy, D. J., & Wagner, C. L. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.418 · Cited by 671 · see citing works
Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522 · see citing works
Elevated circulating tumor necrosis factor levels in Alzheimer's disease
Fillit, H. M., Ding, W., Buée, L., Kalman, J., Altstiel, L. D., LAWLOR, B. A., & Wolf-Klein, G. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90490-k · Cited by 513 · see citing works
Intrathecal inflammation precedes development of Alzheimer's disease
Tarkowski, E. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.9.1200 · Cited by 501 · see citing works
Inflammatory processes in Alzheimer's disease
McGeer, E. G., & McGeer, P. L. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00124-6 · Cited by 473 · see citing works
Lourenco, M. V., Clarke, J. R., Frozza, R. L., Bomfim, T. R., Forny‐Germano, L., Batista, A. F., Sathler, L. B., Brito‐Moreira, J., Amaral, O. B., Silva, C. A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.11.002 · Cited by 415 · see citing works
He, P., Zhong, Z., Lindholm, K., Berning, L., Lee, W., Lemere, C., Staufenbiel, M., Li, R., & Shen, Y. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200705042 · Cited by 390 · see citing works
Liao, Y.-F., Wang, B.-J., Cheng, H.-T., Kuo, L.-H., & Wolfe, M. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402034200 · Cited by 389 · see citing works
Yamamoto, M., Kiyota, T., Horiba, M., Buescher, J. L., Walsh, S. M., Gendelman, H. E., & Ikezu, T. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060378 · Cited by 367 · see citing works
Medeiros, R., Prediger, R. D. S., Passos, G. F., Pandolfo, P., Duarte, F. S., Franco, J. L., Dafre, A. L., Di Giunta, G., Figueiredo, C. P., Takahashi, R. N., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5047-06.2007 · Cited by 292 · see citing works
Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease
Álvarez, A., Cacabelos, R., Sanpedro, C., García-Fantini, M., & Aleixandre, M. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.012 · Cited by 278 · see citing works
TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study.
Tobinick, E. L., Gross, H., Weinberger, A., & Cohen, H. (2006) · PubMed Central · Cited by 271 · see citing works
McAlpine, F. E., Lee, J., Harms, A. S., Ruhn, K. A., Blurton-Jones, M. M., Hong, J. J., Das, P., Golde, T. E., LaFerla, F. M., Oddo, S., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.01.006 · Cited by 269 · see citing works
Janelsins, M. C., Mastrangelo, M. A., Oddo, S., LaFerla, F. M., Federoff, H. J., & Bowers, W. J. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-23 · Cited by 260 · see citing works
Etanercept in Alzheimer disease
Butchart, J., Brook, L., Hopkins, V., Teeling, J. L., Püntener, U., Culliford, D. J., Sharples, R., Sharif, S., McFarlane, B., Raybould, R., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001617 · Cited by 249 · see citing works
Janelsins, M. C., Mastrangelo, M. A., Park, K. M., Sudol, K. L., Narrow, W. C., Oddo, S., LaFerla, F. M., Callahan, L. M., Federoff, H. J., & Bowers, W. J. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.080528 · Cited by 220 · see citing works
Cerebral pattern of pro- and anti-inflammatory cytokines in dementias
Tarkowski, E., Liljeroth, A.-M., Minthon, L., Tarkowski, A., Wallin, A., & Blennow, K. (2003) · Brain Research Bulletin · doi:10.1016/s0361-9230(03)00088-1 · Cited by 219 · see citing works
Shi, J.-Q., Shen, W., Chen, J., Wang, B.-R., Zhong, L.-L., Zhu, Y.-W., Zhu, H.-Q., Zhang, Q.-Q., Zhang, Y.-D., & Xu, J. (2011) · Brain Research · doi:10.1016/j.brainres.2010.10.053 · Cited by 219 · see citing works
Weiss, T., Grell, M., Hessabi, B., Bourteele, S., Müller, G., Scheurich, P., & Wajant, H. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.5.2398 · Cited by 184 · see citing works
The Seminal Role of β-Amyloid in the Pathogenesis of Alzheimer Disease
Joachim, C. L., & Selkoe, D. J. (1992) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199205000-00003 · Cited by 181 · see citing works
Sly, L. M., KRZESICKI, R. F., Brashler, J. R., Buhl, A.-L., McKinley, D. D., Carter, D. B., & Chin, J. E. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00730-4 · Cited by 174 · see citing works
Biopharmaceutical drug targeting to the brain
Pardridge, W. M. (2010) · Journal of drug targeting · doi:10.3109/10611860903548354 · Cited by 172 · see citing works
Human pro-Tumor Necrosis Factor Is a Homotrimer
Tang, P., Hung, M., & Klostergaard, J. (1996) · Biochemistry · doi:10.1021/bi952182t · Cited by 165 · see citing works
Alzheimer's disease: treatments in discovery and development
Citron, M. (2002) · Nature Neuroscience · doi:10.1038/nn940 · Cited by 164 · see citing works
Targeting TNF: a therapeutic strategy for Alzheimer's disease
Cheng, X., Shen, Y., & Li, R. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.06.029 · Cited by 128 · see citing works
Paganelli, R., Iorio, A. D., Patricelli, L., Ripani, F., Sparvieri, E., Faricelli, R., Iarlori, C., Porreca, E., Gioacchino, M. D., & Abate, G. (2002) · Experimental Gerontology · doi:10.1016/s0531-5565(01)00191-7 · Cited by 128 · see citing works
Boado, R. J., Hui, E. K., Lu, J. Z., Zhou, Q.-H., & Pardridge, W. M. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.01.011 · Cited by 111 · see citing works
Cheng, X., Yang, L., He, P., Li, R., & Shen, Y. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1253 · Cited by 102 · see citing works
Montgomery, S. L., Mastrangelo, M. A., Habib, D., Narrow, W. C., Knowlden, S. A., Wright, T. W., & Bowers, W. J. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.07.001 · Cited by 96 · see citing works
Brain Protection from Stroke with Intravenous TNF α Decoy Receptor-Trojan Horse Fusion Protein
Sumbria, R. K., Boado, R. J., & Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.97 · Cited by 95 · see citing works
Self-citationPerry, R. T., Collins, J. S., Harrell, L. E., Acton, R. T., & Go, R. C. P. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1371 · Cited by 81 · see citing works
Detrait, E., Danis, B., Lamberty, Y., & Foerch, P. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.04.001 · Cited by 69 · see citing works
Neuroprotection with a Brain-Penetrating Biologic Tumor Necrosis Factor Inhibitor
Zhou, Q.-H., Sumbria, R. K., Hui, E. K., Lu, J. Z., Boado, R. J., & Pardridge, W. M. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.185876 · Cited by 67 · see citing works
Self-citationAlzheimer’s Disease: Exploring the Role of Inflammation and Implications for Treatment
McCaulley, M. E., & Grush, K. A. (2015) · International Journal of Alzheimer s Disease · doi:10.1155/2015/515248 · Cited by 62 · see citing works
Shi, J., Wang, B., Jiang, W., Chen, J., Zhu, Y., Zhong, L., Zhang, Y., & Xu, J. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03445.x · Cited by 61 · see citing works
Brain-Penetrating Tumor Necrosis Factor Decoy Receptor in the Mouse
Zhou, Q.-H., Boado, R. J., Hui, E. K., Lu, J. Z., & Pardridge, W. M. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.036012 · Cited by 55 · see citing works
Boado, R. J., Hui, E. K., Lu, J. Z., & Pardridge, W. M. (2009) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2009.08.019 · Cited by 53 · see citing works
Biologic TNFα-inhibitors that cross the human blood-brain barrier
Pardridge, W. M. (2010) · Bioengineered Bugs · doi:10.4161/bbug.1.4.12105 · Cited by 49 · see citing works
Sumbria, R. K., Zhou, Q.-H., Hui, E. K., Lu, J. Z., Boado, R. J., & Pardridge, W. M. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400004a · Cited by 47 · see citing works
Self-citationInfliximab ameliorates AD-associated object recognition memory impairment
Kim, D. H., Choi, S., Jho, J., Park, M., Kang, J., Park, S. J., Ryu, J. H., Jo, J., Kim, H. H., & Kim, B. C. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.06.001 · Cited by 37 · see citing works
Jiang, H. X., He, P., Xie, J., Staufenbiel, M., Li, R., & Shen, Y. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu206 · Cited by 36 · see citing works
Sumbria, R. K., Boado, R. J., & Pardridge, W. M. (2013) · Brain Research · doi:10.1016/j.brainres.2013.02.022 · Cited by 34 · see citing works
Self-citationRoerink, M. E., Groen, R. J. M., Franssen, G. M., de Weem, B. L.-V., Boerman, O. C., & van der Meer, J. W. M. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0149-7 · Cited by 20 · see citing works
Targeting tau protein in Alzheimer's disease
Rafii, M. S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32107-9 · Cited by 20 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253 · see citing works
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966 · see citing works
Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease
Dionisio-Santos, D. A., Olschowka, J. A., & O’Banion, M. K. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1453-0 · Cited by 184 · see citing works
Age-related shifts in gut microbiota contribute to cognitive decline in aged rats
Li, Y., Ning, L., Yin, Y., Wang, R., Zhang, Z., Hao, L., Wang, B., Zhao, X., Yang, X., Yin, L., et al. (2020) · Aging · doi:10.18632/aging.103093 · Cited by 125 · see citing works
Reading, C. L., Ahlem, C. N., & Murphy, M. F. (2021) · Neurodegenerative Disease Management · doi:10.2217/nmt-2021-0022 · Cited by 84 · see citing works
Sex-specific DNA methylation differences in Alzheimer’s disease pathology
Zhang, L., Young, J. I., Gomez, L., Silva, T. C., Schmidt, M. A., Cai, J., Chen, X., Martin, E. R., & Wang, L. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01177-8 · Cited by 58 · see citing works
Anti-Neuroinflammatory Potential of Polyphenols by Inhibiting NF-Κb to Halt Alzheimer's Disease
Uddin, M. S., Hasana, S., Ahmad, J., Hossain, M. F., Rahman, M. M., Behl, T., Rauf, A., Ahmad, A., Hafeez, A., Perveen, A., et al. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612826666201118092422 · Cited by 49 · see citing works
Pathogenesis, Animal Models, and Drug Discovery of Alzheimer’s Disease
Xia, Z.-D., Ma, R.-X., Wen, J.-F., Zhai, Y.-F., Wang, Y.-Q., Wang, F.-Y., Liu, D., Zhao, X.-L., Sun, B., Jia, P., et al. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-230326 · Cited by 19 · see citing works
New biologicals and biomaterials in the therapy of Alzheimer's disease
Prajapati, V., Shinde, S., Shrivastav, P., & Prajapati, B. G. (2024) · Alzheimer's Disease and Advanced Drug Delivery Strategies · doi:10.1016/b978-0-443-13205-6.00016-9 · Cited by 7 · see citing works
The mTOR pathway: a common link between Alzheimer's disease and Down Syndrome
Wohlfert, A. J., Phares, J., & Granholm, A.-C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206183 · Cited by 6 · see citing works
- Authors
- Chang, R., Yee, K.-L., & Sumbria, R. K.
- Affiliations
- Keck Graduate Institute (US)
- Corresponding author
- Sumbria, Rachita K
- ORCID
- Sumbria, Rachita K
- Venue
- Journal of Central Nervous System Disease
- Publisher
- SAGE Publications
- Published
- 2017-01-01
- Volume
- 9
- Pages
- 117957351770927
- ISSN
- 1179-5735 (ISSN-L)
- PMC
- PMC5436834
- OpenAlex
- W2616586760
- Cited by
- 195
- References
- 60
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 29 · 2023: 26 · 2022: 29 · 2021: 30 · 2020: 26 · 2019: 19 · 2018: 9 · 2017: 3
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Central Nervous System Disease (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Chapman University Digital Commons (Chapman University) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- TNF-α, Alzheimer's disease, TNF-alpha inhibitors, blood-brain barrier, biologic drug development, neuroinflammation, Alzheimer's disease treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
